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I.  INTRODUCTION 
The Workshop on Biobanking Informatics in NSW 2013 
(WBIN13) was organised by the Translational Cancer Research 
Network (TCRN) to bring together practitioners and researchers 
(Australian and International) with a broad range of expertise in 
the field of Biobanking Informatics to provide a forum for the 
exchange of experiences, ideas and approaches. Details about 
the workshop can be found at https://wbin13.eventbrite.com.au. 
The workshop took place on the 10th of May 2013 in the 
Wallace Wurth Building at the University of New South Wales 
with Professor Nicholas Hawkins moderating the session. 
The aims of the workshop were as follows (1) To assess and 
compare current research in the field of Biobanking Informatics 
in Australia and internationally (2) To identify knowledge gaps 
and priority areas to be addressed (3) To explore the possibility 
for cross-disciplinary collaboration and areas for future joint 
development (4) To provide a forum to foster the development 
of joint research programs and student/staff exchange. Prof. 
Nick kicked off the workshop with discussion on biobanking 
and its place in translational research (Figure 1)[1]. 
 
Figure 1: Biobanking and translational research 
The workshop was separated into a morning and evening 
session. It comprised of ten speeches, and two panel discussions. 
The first keynote speech was delivered in the morning which 
discussed “Cancer Research Information Cloud at Taipei 
Medical University, Taiwan".  After Morning Tea two more 
speeches were conducted, the first was on caTissue an open 
source Biobanking Laboratory Information Management 
System (LIMS), and the second was on integrating Biospecimen 
Management Systems with Anatomical Pathology Laboratory 
Information Systems (LIS) and Digital Pathology Systems. 
After lunch the Second Keynote speech was conducted on the 
US perspectives on biobanking which was followed by a small 
panel discussion. Finally, the workshop concluded with a 
Seminar, which comprised of short presentations from local and 
state perspectives on linking cancer biobanks in NSW as well as 
a final Panel Discussion. 
II. MORNING SESSION 
A. First Speech (Keynote): Cancer Research Information 
Cloud at Taipei Medical University, Taiwan  
Professor Jack Li is a pioneer of Medical Informatics 
research in Taiwan and is the Vice President of Taipei Medical 
University as well as an adjunct professor of Graduate Institute 
of Biomedical Informatics, and President of the Asia Pacific 
Association for Medical Informatics. Professor Li discussed the 
benefits of medical cloud storage for bio-specimen data which 
integrates biospecimen samples from multiple sites.  
The presenter also discussed Taipei Medical University’s 
implementation of this cloud system for their biobank sites and 
emphasized the benefits of providing all biospecimen data 
online which includes the ease of access to biospecimen samples 
for researchers, the improved efficiency for ethics committees to 
approve the use of biospecimens samples as it is done online 
rather than paper based methods, and the possibility of using 
Business Intelligence tools such as Google Motion Chart to 
analyze data, now that it has been collected in one location. 
Another major benefit to cloud based systems is unlimited 
storage in the cloud. It was found that local systems had no 
capacity to store all biospecimen data, and old records had to be 
deleted to “make room” for new data. This resulted in the loss 
of historical data which could be used for further data analysis.   
The system should only hold de-identified data which is 
important in protecting patient confidentiality. Also, every EMR 
record requires consent from ethics committee before being 
published on the cloud. Additionally, all sites are required to 
harmonize their Standard Operating Procedures (SOP) for Cloud 
based systems to be possible. Professor Li suggested other 
countries, including Australia, to adopt a similar cloud based 
approach to biospecimen samples (Figure 2). 
 
Figure 2: Translational Research Cloud 
B. Second speech: caTissue+  
Srikanth Adiga from Krishagni Solutions Pty Ltd discussed 
the program caTissue+ which is an open source Biobanking 
Laboratory Information Management System (LIMS) and the 
possibilities it can provide for integrating biobanks. It has been 
adopted by over 50 biobanks across the globe and, being an open 
source system, has various information/guides available on the 
web.  
C. Third speech: Integrating Biospecimen Management 
System with Anatomical Pathology Laboratory 
Information System (LIS) and Digital Pathology Systems 
Jitendra Jonnagaddala, an Information Manager at TCRN 
presented Integrating Biospecimen Management System with 
Anatomical Pathology Laboratory Information System (LIS) 
and Digital Pathology Systems. The presenter stressed the 
importance of integrated clinical and research systems being 
scalable, flexible, and interoperable. The system developed must 
be generic to allow more information to be loaded into the 
system in the future, as well as allowing additional data types to 
be entered into the system[2].  
The pilot project between Lowy Bio-repository, SEALS, and 
UNSW School of Medical Sciences was also discussed, as well 
as the lessons learned from the integration experience. The pilot 
project linked Aperio (a digital pathology system) and OmniLab 
(Laboratory Information System) using caTissue+. Challenges 
found in integrating the two systems was that the standard 
operating procedures (SOPS) from both Lowy and SEALS were 
extremely different and had to be integrated. Also another hurdle 
was convincing people to use the system. It was also found that 
it was difficult to determine who to talk to when obtaining 
permission and data for Biospecimens. Furthermore, it was 
difficult in gaining trust from the hospital to obtain biospecimen 
data.  
caTissue+ was found to be very flexible and integration 
between the two systems would not have been possible without 
it [3].  Moreover, caTissue+ provides the opportunity for other 
systems to be integrated with the existing system. Any system 
using HL7 could be integrated with caTissue+. 
However, it was also mentioned that having completed this 
project and understanding which people/organizations need to 
be consulted in order to obtain the necessary authority to 
integrate systems. Similar projects in the future can be 
completed in a much shorter timeframe. 
D. Fourth Speech (Keynote): US perspective 
Dr. Jim Vaught is the Deputy Director of the U.S. National 
Cancer Institute’s (NCI) Office of Biorepository and 
Biospeicmen Research Banks (BBRB). Dr. Vaught discussed 
several issues (1) biobanking business planning and 
sustainability options (2) international sample/data access and 
research collaboration and (3) Translational and economic 
impacts of biobanking. 
The speech began with the various issues faced in the United 
States with collecting bio-specimens from various sites and also 
in obtaining permission required to use the samples and how 
Australia could learn from it when integrating our systems[4]. 
NCI best practices for biospecimen resources and the adoption 
by others was considered critical in getting good quality samples 
as studies showed there were discrepancies between biobanks in 
storing samples (i.e. samples stored at different temperatures) 
which led to many samples being collected that were 
unusable[5]. It was found that once NCI best practices were 
implemented, sample quality did indeed improve. It is noted that 
it has not been established whether it is feasible for 
implementing best practices yet. 
Another major issue found in the US model was obtaining 
permission for the biospecimen samples[6]. Different samples 
were owned by different centers, and sometimes multiple 
centers. To overcome this, a workshop was required to get all 
relevant stakeholders to collaborate and produce a standardized 
best practices. NSW needs to achieve something similar to unify 
our centers. 
E. Fifth Speech: using CTRNet approach to link biobanks 
though education 
Dr. Peter Watson is a Professor in the Department of 
Pathology, BC Cancer Agency and the University of British 
Columbia who presented “The CTRNet (Canadian Tumour 
Repository Network) approach to linking biobanks through 
education and support”[7]. He began by describing the quality 
issues faced in Canada due to a lack of standardization in SOP 
which resulted in a lack of capacity to meet demand, and reduced 
efficiency. The response was to create a certification program 
where all biobanks certified has undertaken fundamental 
training and are approved by the ethics board in Canada. All 
biobanks were to use the same SOP, and had shared governance 
between pathology and biobanks. This certification process has 
improved the quality of biospecimens collected and the program 
has been developed for international usage. 
F. Sixth Speech: opportunities for Australian biobanks 
Dr. Nik Zeps is a PhD scientist from the University of 
Western Australia who presented “opportunities for Australian 
biobanks”. Dr. Zeps pointed out that that Western Australia also 
faced similar problems to Canada in that many samples collected 
by biobanks were not up to standard. He also discussed many 
issues with Australian biobanks, in that they are fragmented, 
inefficient and present difficulties for access and recruitment. He 
also discussed the Cancer Council’s findings that a majority of 
Australian biobanks are solely tissue based, have poor linkage to 
medical data, have limited linkage to lifestyle data, are too small 
to be research effective, and have not been designed as a truly 
open source of access. Also there was difficulty in gaining 
consent and ethical approvals due to the ethics board requiring a 
comprehensive statement of approval, rather than a simple 
statement from the patients permitting the use of their tissue[8-
10]. 
Dr. Zeps concluded his speech with suggesting Australia 
should adopt a plan to have our systems centralized (data 
collected from local sites and sent to the hub), distributed (local 
nodes manage collection, processing and storage until required) 
and networked (with independent biobanks integrated by 
informatics solutions)[11]. 
It was also stressed how a scientific approach should be 
taken towards Informatics rather than an opinion based approach 
and that the Canada model of networking is key to sharing data 
between biobanks. 
G. Panel Discussion 
A panel discussion comprised of 3 people, Dr. Jim Vaught, 
Dr. Peter Watson and Dr. Nik Zeps was then conducted. Several 
questions were asked, including how we can deal with the legacy 
issue of biobanks, and governance issues. There was also a 
healthy discussion on methods of convincing the Australian 
public that biobanks are important and should be funded as well 
as the ideal governance structure for Australian biobanks. 
III. EVENING SESSION 
After the panel discussion the Seminar on “Linking cancer 
biobanks in NSW and what can we learn from others” was 
conducted with Professor Nicholas Hawkins once again as the 
Moderator. The session was comprised of a series of short 
presentations of local and state perspectives on the benefits of 
interoperability between biobanks at an information level. It was 
then followed by an interactive panel discussion that drew on 
international experiences in this area. 
A. Seventh speech: The NSW State Experience 
Professor Anna deFazio is the Head of the Gynaecological 
Oncology Research Group at the Westmead Millennium 
Institute and a Professor at the Sydney West Translational 
Cancer Research Centre. Professor deFazio presented the NSW 
experience of getting interoperability between biobanks and 
highlighted the difficulty in linking biobanks with the different 
translational research centres that have been established with the 
cancer institute of NSW especially as there are multiple types of 
biobanks which include multi biobanks, and biobanks with 
multiple nodes[12, 13]. 
Professor deFazio first discussed the Australian ovarian 
cancer study which recruited 1859 women with ovarian, 
fallopian tube, and primary peritoneal cancer from around 
Australia. All samples were collected using standardized 
operation procedures and project contributed to over 120 
publications since 2007 and more than 90 projects approved.   
From very beginning it was known that it would be costly to 
undertake this project. The cost to use each biospecimen array 
was over $1000 in early days. It was therefore essential to ensure 
that these specimens had high quality metadata. The question 
was how to collect the data from many different databases in an 
efficient, yet effective method. In terms of access, hospitals and 
clinics were willing to provide access to their biospecimen 
databases. A common issue was found that much of the data 
within the databases were incomplete due to a lack of SOP as 
well as data on the same patient being spread between multiple 
centers. It was found that some databases did not even have a 
data dictionary. The problem was that there was no 
standardization of data as the QC (person who enters data) was 
often inexperienced, some being clinical students. It was decided 
against stripping data from the databases due to the Governance 
issues as well as the paramount amount of money that needed to 
be spent on it to complete the data. 
The solution used was the clinical trials approach to train 
researchers to recruit patients from the various databases to 
complete clinical report forms, using a standard set of 
guidelines[14]. A help desk facility was also established to 
ensure that everyone extracting medical records knew what they 
were doing. Once the information was collected, information 
was sent to a manager and every form was monitored for 
irregularities. Any query with the data was sent to the center to 
ensure that data being entered into the database is complete. It 
was found that this method produced good quality data; however 
this approach was only possible as the number of patients 
sampled was small since the data collected was from a single 
disease and was collected from a single state.  This method was 
therefore not recommended for a state-wide implementation. 
A more efficient method needs to be found to replicate what 
was achieved in the AOCS on a state-wide basis, whilst 
maintaining data quality. One of the major problems found in 
integrating biobanks is the variance in the data dictionaries, 
created as a result of multiple cancer types. From this study, it 
was found that data definitions were especially important as it 
was difficult to cross check data types (Figure 3). 
 
Figure 3: Summary of terminologies used 
B. Eighth Speech: The Victorian Experience 
Dr. Carmel Murone presented “The Victorian Experience”. 
She is a research scientist who has worked in the Tumour 
Targeting program of the Ludwig Institute for Cancer Research 
since 1998 as well as maintaining the Austin Health Tissue Bank 
and fostering its transition to become a member of the Victorian 
Cancer Biobank. 
Dr. Murone discussed how the four main independent 
biobanks in Victoria were integrated.  All biobanks used a 
standard patient consent form, as well as standard operating 
procedures in collecting tissues. One of the biggest incentives 
for all sites to agree to integration was government funding. The 
backing of the Victorian government was critical in the success 
of the project, which the government did to promote local, 
national and international collaboration. The integration of the 4 
biobanks reduced duplication of resources for collection and 
administration of specimen samples. 
The operation model was based on a “hub and spokes 
model”. The four independent tissue banks jointly designed the 
standard operating procedures, and four biospecimen banks 
were used to store the biospecimen samples from the 27 
hospitals around them. Researchers can now lodge a single 
application to the Cancer Council Victoria Group for all 
biospecimens registered with the group in comparison to the 
previous system where each application had to be made to each 
individual hospital who owned the biospecimen, which then 
needed to be approved by the respective hospital ethics board. 
The inventory now has over 400,000 biospecimens from over 
20,000 donors, and supports 140 research projects by providing 
more than 28,000 samples to researchers locally, nationally and 
internationally. It was also found that researchers are requesting 
more clinical management and outcome data to fully interpret 
their research findings, due to the improvement in infrastructure 
in Victoria. 
Future improvements to the database include linking digital 
images with biospecimen data, making it web-based, holding 
information about the application lodged, and an invoicing 
model for cost recovery. NSW needs to adopt a similar stance in 
unifying our biobanks under one body to simplify the process of 
obtaining biospecimen samples to improve healthcare. 
C. Ninth Speech: What OHMR wants 
Dr. Tony Penna is the Director at the Office for Health and 
Medical Research (OHMR) and presented “What OHMR 
wants”. Dr. Penna discussed OHMR’s recent research in NSW 
biobanks and how OHMR has worked with research 
stakeholders including LHDs, CINSW, MRIs, and other 
Universities in addressing and implementing recommendations 
to ensure the sustainability for existing research assets with a 
particular focus on biobanking, bioinformatics, population-
based cohort studies and record linkage. OHMR is also working 
closely with the cancer institute NSW to develop a state-wide 
biobanking framework, with the aim to improve the accessibility 
to samples and data. 
D. Tenth Speech: IT Options and Issues 
Jeff Christensen from Intersect discussed the IT options and 
issues with biobanking. Intersect’s role was to provide a state-
wide approach to high level IT work to provide a window to 
national programs. They have researched six biobanks and 
found that the operational procedures of each of the biobanks 
and IT platforms are fairly similar. The question is scope and 
how hospitals can be linked from different jurisdictions. It was 
found that databases sharing data would be a more realistic 
integration approach as opposed to all sites using one central 
system. Several issues found when integrating biobank IT 
systems are firewalls, network bandwidth/traffic charges 
(especially for hospitals when uploading large images). 
E. Panel Discussion  
The meeting concluded with a panel discussion which 
provided the opportunity for attendees to question the panel on 
issues with biobanking in NSW. Answers were provided by not 
only the panel but other members of the audience. 
One topic of discussion was the barriers stopping Australia 
from the registration and accreditation of biobanks on a national 
level[15]. The resolution was that there was not a trusted body 
recognized nationally that could certify or police the system. A 
suggestion was for Australia to hold a national workshop to 
bring together biobank researchers and stakeholders to establish 
a trusted central body. 
Another issue discussed was the need for web-based systems 
for biobanks so that researchers can request data online through 
a standardized form. Westmead has already implemented this 
web-based system where researchers lodge an expression of 
interest form which is filled out online. Emails are then sent 
automatically to administrative/access committee for approvals. 
It would be desirable for a state-wide implementation of this 
web-based system in NSW.  
Another question was how NSW could promote/make 
visible the samples that are already stored in our biobanks and 
make it readily available to researchers.  Some solutions NSW 
could follow include MIH which has a biospecimen resource 
locator, or the Canadian model which has a public registry and 
which biobanks can voluntarily join which is part of their 
certification program[16]. Another reason for the reduced 
visibility of samples is in the search functions for biospecimen 
databases. Care must be taken to ensure a simpler search 
function is used as opposed to a complex function which tends 
to freeze the system or produce no results. Currently the best 
option when obtaining biospecimen samples is for researchers to 
communicate with the biobank directly as it provides the 
opportunity for biobank staff to question researchers and 
determine the most appropriate biospecimen sample. 
IV. CONCLUDING REMARKS 
In summary, the workshop was very successful. We had a 
number of speeches from different perspectives on how 
biobanking practices and informatics could be improved in 
NSW and Australia as a whole. We also had two very 
informative panel discussions which provided the opportunity 
for all who attended to ask questions and receive responses from 
not only the panel but other members of the audience. The 
presentations of the workshop can be downloaded from the 
following link - http://tcrn.unsw.edu.au/tcrn-workshop-
biobanking-informatics-nsw-2013-wbin13.  
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